# FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer

> **NCT00646607** · PHASE3 · COMPLETED · sponsor: **Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente** · enrollment: 3756 (actual)

## Conditions studied

- Colon Cancer

## Interventions

- **DRUG:** FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)
- **DRUG:** FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)

## Key facts

- **NCT ID:** NCT00646607
- **Lead sponsor:** Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2013-04
- **Final completion:** 2014-11
- **Target enrollment:** 3756 (ACTUAL)
- **Last updated:** 2014-11-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00646607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00646607, "FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00646607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*